The term sarcopenia, derived from the Greek words sarx for flesh and penia for loss, was first
introduced by Rosenberg 1 in 1989 to describe the loss of muscle mass that accompanies …

Sarcopenia has recently emerged as a new condition that, independently from malnutrition,
may adversely affect the prognosis of cancer patients. Purpose of this narrative review is to …

Most patients with pancreatic adenocarcinoma (PDAC) suffer cachexia; some do not. To
model heterogeneity, we used patient-derived orthotopic xenografts. These phenocopied …

It has frequently been shown that patients with cancer are one of the largest hospital patient
groups with a prevalence for malnutrition. Weight loss is a frequent manifestation of …

Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …

Cancer cachexia (ie, skeletal muscle wasting with or without fat loss) relates to several
adverse outcomes. Computed tomography (CT) cross-sectional images serve as an efficient …

Background Nutritional impairment is common in cancer patients and is associated with
poor outcomes. Only few studies focused on cachexia. We assessed the prevalence of …

In several diseases, low muscle mass has been revealed as an unfavorable prognostic
factor for outcome. Whether this holds true in patients with solid malignancies as well has …

Cancer cachexia is a syndrome characterized by weight loss with accompanying loss of
muscle and/or fat mass and leads to impaired patient function and physical performance and …

Body composition has gained increasing attention in oncology in recent years due to fact
that sarcopenia has been revealed to be a strong prognostic indicator for survival across …